Scientific poster shows the importance of detecting real-time prostate motion using RayPilot®
A poster from the Italian radiotherapy clinic Humanitas Gavazzeni in Bergamo has recently been presented at an Italian congress about stereotactic body radiation therapy (SBRT) in Milan. The meeting was organized by the Italian medical physics association (AIFM) and the University of Milan under the patronage of the Italian association of radiotherapy and oncology (AIRO). Humanitas Gavazzeni has used the RayPilot® to detect real-time prostate motion during ongoing radiotherapy and to evaluate the margin needed.
Physicist Alessandro Vai and colleagues is presenting results that shows prostate motion more than 11 mm detected with the electromagnetic tracking system RayPilot during ongoing treatment, which normally cannot be detected during conventional radiotherapy.
The clinic has used the RayPilot at traditional 39 treatment fractions to learn more about prostate motion and the related effects with the aim to start hypofractionated treatments in the future.
Hypofractionation can result in increased efficiency and cost saving for health care systems. In order to do this in a safe way it is important to know the tumor position also during ongoing radiation.
In the conclusion Alessandro Vai with colleagues suggest that:
- Intrafraction motion impact on treatment margins should be considered
- Variation in DVH analysis for bladder and rectum are not negligible
The conclusion is that target reposition or beam-gating techniques should be considered in the therapy execution protocols.
– It is very important to take the organ motion that occurs during treatment into account in order to choose the right margins around the tumor. This is especially essential at hypofractionation treatments says physicist Alessandro Vai at the radiotherapy clinic Humanitas Gavazzeni in Bergamo.
RayPilot is an electromagnetic tracking system that is used together with existing linear accelerators in order to track prostate motion 30 times a second. A unique interface to Varian IX and Triology linear accelerators for gating and automatic patient set-up has recently been released.
– We see clearly that the knowledge and awareness of the internal organ motions increases in the radiotherapy community. We also see that the interest for hypofractionation is growing. To implement hypofractionation and to reduce the margins safely, the tumor must be localized in real-time during treatment. This can be achieved with RayPilot, says Hanna Syrén Application Manager at Micropos.
For additional information:
Tomas Gustafsson, CEO, Micropos Medical AB (publ), +46-31-772 80 99
About Micropos Medical AB (publ):
Micropos Medical AB (publ) (www.micropos.se) is a Swedish company that has developed the RayPilot® system, which is an electromagnetic positioning and real time tracking system for a fast and objective set-up and for continuous positioning during radiotherapy. A precise and safe localization of the tumor can dramatically improve the outcome of the treatment, particularly for hypofractionated protocols. The RayPilot® system consists mainly of three parts; one transmitter that is placed close by the tumor, a receiving system that is placed directly on the treatment couchtop and software that continuously shows the precise tumor location, and hence where to focus the linac beam. RayPilot® has a unique gating solution qualified and compatible for use with Varian’s Clinac® iX linear accelerators and Trilogy® systems. During 2015 Micropos will release an upcoming RayPilot® transmitter for positioning, in-situ dosimetry and automatic patient identification. RayPilot® is CE certified for prostate use. Follow us on Facebook, www.facebook.com/MicroposMedical. The Micropos share is traded under the stock ticker MPOS.